Logo

Vaxcyte Reports the First Patient Dosing of VAX-24 in P-I/II Study for the Prevention of Invasive Pneumococcal Disease and Pneumonia

Share this

Vaxcyte Reports the First Patient Dosing of VAX-24 in P-I/II Study for the Prevention of Invasive Pneumococcal Disease and Pneumonia

Shots:

  • The first participants has been dosed in the P-I/II clinical study to evaluate VAX-24 vs Prevnar 20 in healthy adults with IPD and Pneumonia at ~13 sites in the US. The results are expected at the end of 2022
  • The P-I of the study is to evaluate the safety and tolerability of a single inj. of VAX-24 at three dose levels in 64 healthy adults aged 18 to 49yrs. while the P-II portion of the study will evaluate the safety, tolerability, and immunogenicity of VAX-24 in ~800 healthy adults aged 50 to 64yrs.
  • The prespecified immunogenicity EPs of the P-II portion of the study include an assessment of the induction of Ab responses using IgG and OPA at three doses

 Ref: Globe Newswire | Image: Vaxcyte

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions